Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Fineline Cube May 20, 2026
Company Deals

Hybio Pharmaceutical Partners with Undisclosed Chinese Firms for GLP-1 API Commercialization in Americas Markets

Fineline Cube May 20, 2026
Company Deals

Shandong Buchang Pharmaceuticals Secures Exclusive License for KYN003 Broad-Spectrum Influenza Vaccine Through Strategic Partnership with Hefei Keyinuo

Fineline Cube May 20, 2026
Company Deals

Boston Scientific Invests $1.5B for 34% Stake in MiRus, Secures Option to Acquire SIEGEL TAVR Business for Additional $3B

Fineline Cube May 19, 2026
Company Deals

Henlius Biotech Secures Exclusive China Rights to CTFH’s Third-Generation EGFR TKI FHND9041 for NSCLC

Fineline Cube May 19, 2026
Policy / Regulatory

China Tightens Medical Insurance Personal Account Oversight with Mandatory “White List” for Retail Pharmacy Purchases

Fineline Cube May 19, 2026
Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Fineline Cube May 20, 2026
Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Fineline Cube May 20, 2026
Company Deals

Shanghai Pharmaceuticals Partners with Baiyun District for Health Initiative

Fineline Cube Mar 3, 2023

China-based Shanghai Pharmaceuticals Holding Co., Ltd (SHA: 601607) has entered into a strategic cooperation agreement...

Company Deals

TandemAI Secures $35M Series A to Expand Drug Discovery Platform

Fineline Cube Mar 3, 2023

TandemAI, a technology firm with operations in New York, San Diego, and China, has successfully...

Company Drug

Merck Reports 12.9% Sales Growth in 2022 Annual Report

Fineline Cube Mar 3, 2023

German major Merck (NYSE: MRK) released its 2022 annual report this week, showing a robust...

Policy / Regulatory

NHSA Releases Guidelines on Drug Procurement and Pricing Management

Fineline Cube Mar 2, 2023

The National Healthcare Security Administration (NHSA) has released a notification regarding provincial centralized procurement and...

Company Deals

Kinnjiu Biopharma Initiates Global Phase I Study for Exarafenib

Fineline Cube Mar 2, 2023

Shanghai-based Kinnjiu Biopharma Inc. has announced the first subject dosing in the global multi-center Phase...

Company

Zai Lab Reports 2022 Financial Results with Revenue Growth

Fineline Cube Mar 2, 2023

China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has announced its full-year 2022 financial results,...

Company Deals

Pengyang Yiliao Raises Series B+ Funds for Cardiovascular Product Development

Fineline Cube Mar 2, 2023

Pengyang Yiliao, a Beijing-based developer and manufacturer of cardiovascular technology, has reportedly raised “tens of...

Company Drug

Zhejiang Medicine’s ARX788 Shows Positive Results in Breast Cancer Study

Fineline Cube Mar 2, 2023

China-based Zhejiang Medicine Co., Ltd (SHA: 600216) has announced positive results from a Phase II/III...

Company Deals

Glowe Raises Series A+ Funding to Expand AIGC in Mental Health

Fineline Cube Mar 2, 2023

Glowe, an online psychological consultation platform based in Guangdong, has reportedly raised “tens of millions”...

Company Deals

Geneus Tech Secures Funding for Gseq500 Gene Sequencer Production

Fineline Cube Mar 2, 2023

Geneus Tech, a Shenzhen-based developer and manufacturer of gene sequencers, has reportedly raised an undisclosed...

Company Deals

Alphamab Oncology Partners with Stemirna for BsAb and mRNA Vaccine Development

Fineline Cube Mar 2, 2023

China-based Alphamab Oncology (HKG: 9966) has announced a strategic partnership with Shanghai-based mRNA drug developer...

Company Drug

CanSino Biologics’ Inhalable COVID-19 Vaccine Gets EUA in Indonesia

Fineline Cube Mar 2, 2023

China-based CanSino Biologics (SHA: 688185, HKG: 6185) has announced that it has received emergency use...

Company Deals

BeiGene Reports Outstanding Q4 and Full-Year 2022 Financial Results

Fineline Cube Mar 1, 2023

BeiGene, Ltd. (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has released financial results for the Q4...

Company

Viatris Reports Q4 2022 Results, Highlights China Growth

Fineline Cube Mar 1, 2023

US-based generics giant Viatris Inc. (NASDAQ: VTRS) has released its Q4 2022 financial report. The...

Company Medical Device

China Performs First AB-BNCT Procedures Outside Japan

Fineline Cube Mar 1, 2023

The first accelerator-based boron neutron capture therapy (AB-BNCT) procedures have been performed in China by...

Company

HutchMed Reports 2022 Financial Results with Revenue Growth

Fineline Cube Mar 1, 2023

Hutchison China Meditech (HutchMed; HKG: 0013, NASDAQ: HCM) has released its financial results for the...

Company Drug

3SBio’s Nalfurafine Tablets Accepted for Review by NMPA for Chronic Liver Disease

Fineline Cube Mar 1, 2023

China-based 3SBio Inc. (HKG: 1530) has announced that a clinical trial filing for its nalfurafine...

Company Deals

3SBio Terminates Distribution Agreement with AstraZeneca for Byetta

Fineline Cube Mar 1, 2023

China-based 3SBio Inc. (HKG: 1530) has announced the termination of a distribution agreement with UK...

Company Drug

JW Therapeutics Initiates Clinical Study for JWATM214 in Advanced Hepatocellular Carcinoma

Fineline Cube Mar 1, 2023

China-based JW Therapeutics (HKG: 2126) has announced the initiation of a clinical study for its...

Company

FibroGen Reports Q4 2022 Financial Results with Revenue Growth

Fineline Cube Mar 1, 2023

US-based FibroGen Inc. (FGEN) has released its Q4 2022 financial results. The company reported global...

Posts pagination

1 … 559 560 561 … 669

Recent updates

  • CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus
  • Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study
  • Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law
  • Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study
  • China Population Welfare Foundation and Lilly China Launch “Tuohu Chang’an” Patient Assistance Program for Inflammatory Bowel Disease
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

CBC Group and Global Healthcare Opportunities Merge to Create $21 Billion Healthcare Investment Colossus

Company Drug

Sanofi’s Efdoralprin Alfa Demonstrates Superior fAAT Normalization in Alpha-1 Antitrypsin Deficiency Phase II ElevAATe Study

Others

Takeda Faces $885M Antitrust Verdict in Amitiza “Pay-for-Delay” Litigation; Damages to be Trebled Under U.S. Law

Company Drug

Novartis’ Pluvicto Demonstrates Significant PSA Response Improvement in PSMA-Positive mHSPC Patients in PSMAddition Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.